ReviewClinical & developmental immunology2011
The immune response to tumors as a tool toward immunotherapy.
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Association of blood cell-based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study.Cancer medicine · 2024Article
- Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma.Frontiers in immunology · 2023Article
- mRNA vaccines for cancer immunotherapy.Frontiers in immunology · 2022Review
- Imaging in Tumor Immunology.Nuclear medicine and molecular imaging · 2021Review
- Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives.Vaccines · 2021Review
- SMARCB1 Acts as a Quiescent Gatekeeper for Cell Cycle and Immune Response in Human Cells.International journal of molecular sciences · 2020Article
- Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer.Cancers · 2019Review
- Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy.Journal of clinical medicine · 2019Review
- The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.International journal of molecular sciences · 2019Review
- Bioactive Nanoparticles for Cancer Immunotherapy.International journal of molecular sciences · 2018Review
- Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders.Mediators of inflammation · 2018Review
- A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.PloS one · 2017Article
- Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer.Oncology letters · 2016Article
- Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients.Immunologic research · 2016Article
- Selective phosphorylation of the Dlg1AB variant is critical for TCR-induced p38 activation and induction of proinflammatory cytokines in CD8+ T cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Gene expression correlation for cancer diagnosis: a pilot study.BioMed research international · 2014Article
- Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Journal for immunotherapy of cancer · 2014Review
- Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Scientifica · 2013Review
- Recovery of immunological homeostasis positively correlates both with early stages of right-colorectal cancer and laparoscopic surgery.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently cancer medical therapy was limited to chemotherapy that could not differentiate cancer cells from normal cells. More recently with the remarkable mushroom of immunology, newer tools became available, resulting in the novel possibility to attack cancer with the specificity of the immune system. Herein we will review some of the recent achievement of immunotherapy in such aggressive cancers as melanoma, prostatic cancer, colorectal carcinoma, and hematologic malignancies. Immunotherapy of tumors has developed several techniques: immune cell transfer, vaccines, immunobiological molecules such as monoclonal antibodies that improve the immune responses to tumors. This can be achieved by blocking pathways limiting the immune response, such as CTLA-4 or Tregs. Immunotherapy may also use cytokines especially proinflammatory cytokines to enhance the activity of cytotoxic T cells (CTLs) derived from tumor infiltrating lymphocytes (TILs). The role of newly discovered cytokines remains to be investigated. Alternatively, an other mechanism consists in enhancing the expression of TAAs on tumor cells. Finally, monoclonal antibodies may be used to target oncogenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.